Correlation Between NextCell Pharma and Cantargia

Can any of the company-specific risk be diversified away by investing in both NextCell Pharma and Cantargia at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NextCell Pharma and Cantargia into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NextCell Pharma AB and Cantargia AB, you can compare the effects of market volatilities on NextCell Pharma and Cantargia and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NextCell Pharma with a short position of Cantargia. Check out your portfolio center. Please also check ongoing floating volatility patterns of NextCell Pharma and Cantargia.

Diversification Opportunities for NextCell Pharma and Cantargia

-0.36

Correlation Coefficient

NextCell Pharma  Cantargia

Very good diversification

The 3 months correlation between NextCell and Cantargia is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding NextCell Pharma AB and Cantargia AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cantargia AB and NextCell Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NextCell Pharma AB are associated (or correlated) with Cantargia. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cantargia AB has no effect on the direction of NextCell Pharma i.e., NextCell Pharma and Cantargia go up and down completely randomly.

Pair Corralation between NextCell Pharma and Cantargia

Assuming the 90 days trading horizon NextCell Pharma AB is expected to generate 0.68 times more return on investment than Cantargia. However, NextCell Pharma AB is 1.48 times less risky than Cantargia. It trades about 0.14 of its potential returns per unit of risk. Cantargia AB is currently generating about -0.17 per unit of risk. If you would invest  128.00  in NextCell Pharma AB on September 2, 2024 and sell it today you would earn a total of  47.00  from holding NextCell Pharma AB or generate 36.72% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

NextCell Pharma AB  vs.  Cantargia AB

NextCell Pharma AB

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in NextCell Pharma AB are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, NextCell Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Cantargia AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cantargia AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with NextCell Pharma and Cantargia

The main advantage of trading using opposite NextCell Pharma and Cantargia positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NextCell Pharma position performs unexpectedly, Cantargia can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cantargia will offset losses from the drop in Cantargia's long position.

The idea behind NextCell Pharma AB and Cantargia AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.